775 related articles for article (PubMed ID: 32983132)
1. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies.
Siegler EL; Kenderian SS
Front Immunol; 2020; 11():1973. PubMed ID: 32983132
[TBL] [Abstract][Full Text] [Related]
2. Reactions Related to CAR-T Cell Therapy.
Miao L; Zhang Z; Ren Z; Li Y
Front Immunol; 2021; 12():663201. PubMed ID: 33995389
[TBL] [Abstract][Full Text] [Related]
3. Management of T-Cell Engaging Immunotherapy Complications.
Varadarajan I; Lee DW
Cancer J; 2019; 25(3):223-230. PubMed ID: 31135530
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
Front Immunol; 2021; 12():611366. PubMed ID: 33708205
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies.
Xiao X; Huang S; Chen S; Wang Y; Sun Q; Xu X; Li Y
J Exp Clin Cancer Res; 2021 Nov; 40(1):367. PubMed ID: 34794490
[TBL] [Abstract][Full Text] [Related]
6. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
[TBL] [Abstract][Full Text] [Related]
7. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
Freyer CW; Porter DL
J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
[TBL] [Abstract][Full Text] [Related]
8. CAR-T cell: Toxicities issues: Mechanisms and clinical management.
Wallet F; Sesques P; Devic P; Levrard M; Ader F; Friggeri A; Bachy E
Bull Cancer; 2021 Oct; 108(10S):S117-S127. PubMed ID: 34920794
[TBL] [Abstract][Full Text] [Related]
9. Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia.
Hong F; Shi M; Cao J; Wang Y; Gong Y; Gao H; Li Z; Zheng J; Zeng L; He A; Xu K
J Cell Mol Med; 2021 Dec; 25(24):11063-11074. PubMed ID: 34734474
[TBL] [Abstract][Full Text] [Related]
10. Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy.
Walton ZE; Frigault MJ; Maus MV
Expert Opin Pharmacother; 2024 Feb; 25(3):263-279. PubMed ID: 38588525
[TBL] [Abstract][Full Text] [Related]
11. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.
Ruff MW; Siegler EL; Kenderian SS
Neurol Clin; 2020 Nov; 38(4):953-963. PubMed ID: 33040871
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy.
Tedesco VE; Mohan C
J Immunol; 2021 Apr; 206(7):1561-1568. PubMed ID: 33692146
[TBL] [Abstract][Full Text] [Related]
13. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
[TBL] [Abstract][Full Text] [Related]
14. Cellular therapy: Immune-related complications.
Oved JH; Barrett DM; Teachey DT
Immunol Rev; 2019 Jul; 290(1):114-126. PubMed ID: 31355491
[TBL] [Abstract][Full Text] [Related]
15. Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies.
Yang C; Nguyen J; Yen Y
J Biomed Sci; 2023 Oct; 30(1):89. PubMed ID: 37864230
[TBL] [Abstract][Full Text] [Related]
16. Managing the toxicities of CAR T-cell therapy.
Neelapu SS
Hematol Oncol; 2019 Jun; 37 Suppl 1():48-52. PubMed ID: 31187535
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
Kotch C; Barrett D; Teachey DT
Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357
[No Abstract] [Full Text] [Related]
18. Continuous blood purification successfully treated severe cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy: A case report.
Zhang F; Jia XL; Zuo YX; Lu AD; Zhang PF; Xue L; Zhang LP
Pediatr Blood Cancer; 2022 Aug; 69(8):e29563. PubMed ID: 35044056
[No Abstract] [Full Text] [Related]
19. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.
Sterner RC; Sterner RM
Front Immunol; 2022; 13():879608. PubMed ID: 36081506
[TBL] [Abstract][Full Text] [Related]
20. Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study.
Gutierrez C; Brown ART; May HP; Beitinjaneh A; Stephens RS; Rajendram P; Nates JL; Pastores SM; Dharshan A; de Moraes AG; Hensley MK; Feng L; Brudno JN; Athale J; Ghosh M; Kochenderfer JN; Arias AS; Lin Y; McEvoy C; Mead E; Westin J; Kostelecky N; Mian A; Herr MM
Crit Care Med; 2022 Jan; 50(1):81-92. PubMed ID: 34259446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]